ALLMedicine™ Adult-onset Still's Disease Center
Research & Reviews 322 results
https://clinicaltrials.gov/ct2/show/NCT03510442
Mar 27th, 2023 - The purpose of this protocol is to study the natural history, genetics and pathophysiology of systemic juvenile idiopathic arthritis (sJIA), adult-onset Still s disease (AOSD) and related inflammatory conditions. One of seven subtypes of juvenile ...
https://doi.org/10.1093/rheumatology/kead125
Rheumatology (Oxford, England); Farina N, Arroyo-Sánchez D et. al.
Mar 18th, 2023 - Adult-onset Still's disease complicated by Guillain-Barré syndrome.|2023|Farina N,Arroyo-Sánchez D,Campochiaro C,Dagna L,Tomelleri A,|
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999054
Orphanet Journal of Rare Diseases; Gottschalk MN, Heiland M et. al.
Mar 11th, 2023 - Adult-onset Still's disease (AOSD) is a multi-system, auto-inflammatory disease characterized by fever, arthralgia, typical rash, leukocytosis, sore throat, and liver dysfunction, among other symptoms. Retrospective studies about the frequencies o...
https://clinicaltrials.gov/ct2/show/NCT05001737
Feb 21st, 2023 - Study NI-0501-14 is a two-cohort trial that enrolls subjects who are diagnosed with sHLH/MAS (MAS being a form of secondary HLH) and who are presenting an inadequate response to high doses of GCs. These subjects will be enrolled in 2 cohorts as pe...
https://doi.org/10.1016/j.autrev.2023.103295
Autoimmunity Reviews; Manfredi M, Van Hoovels L et. al.
Feb 14th, 2023 - Calprotectin (CLP) is a heterodimeric complex formed by two S100 proteins (S100A8/A9), which plays a pivotal role in innate immunity. Due to its intrinsic cytotoxic and proinflammatory properties, CLP controls cell differentiation, proliferation a...
Clinicaltrials.gov 13 results
https://clinicaltrials.gov/ct2/show/NCT03510442
Mar 27th, 2023 - The purpose of this protocol is to study the natural history, genetics and pathophysiology of systemic juvenile idiopathic arthritis (sJIA), adult-onset Still s disease (AOSD) and related inflammatory conditions. One of seven subtypes of juvenile ...
https://clinicaltrials.gov/ct2/show/NCT05001737
Feb 21st, 2023 - Study NI-0501-14 is a two-cohort trial that enrolls subjects who are diagnosed with sHLH/MAS (MAS being a form of secondary HLH) and who are presenting an inadequate response to high doses of GCs. These subjects will be enrolled in 2 cohorts as pe...
https://clinicaltrials.gov/ct2/show/NCT02780583
Feb 13th, 2023 - Macrophage activation syndrome (MAS) is a disorder whereby the immune system generates very high levels of substances (cytokines) that promote inflammation to the extent dysfunction occurs in multiple organ systems which if unchecked, is frequentl...
https://clinicaltrials.gov/ct2/show/NCT03311854
May 17th, 2022 - Macrophage Activation Syndrome (MAS) is a rare, life-threatening condition characterized by uncontrolled hyperinflammation which may develop on the background of systemic Juvenile Idiopathic Arthritis (sJIA) or Adult-onset Still's Disease (AOSD). ...
https://clinicaltrials.gov/ct2/show/NCT05102695
Nov 5th, 2021 - Inflammatory markers are often elevated in patients with COVID-19, notably C-reactive protein (CRP), D-dimer, lactate dehydrogenase (LDH), IL-6and ferritin. Multiple prior studies have found correlations between various biomarkers and clinical out...
News 11 results
https://www.medscape.com/viewarticle/948506
Apr 1st, 2021 - The National Institute for Health and Care Excellence (NICE) has recommended anakinra (Kineret, Swedish Orphan Biovitrum) as a treatment option for Still’s disease in adults and systemic juvenile idiopathic arthritis in children. Anakinra is an in...
https://www.medscape.com/viewarticle/932625
Jun 19th, 2020 - The Food and Drug Administration has expanded the indications for canakinumab (Ilaris) to include all patients with active Still's disease older than 2 years, adding adult-onset Still's disease (AOSD) to a previous approval for juvenile-onset Stil...
https://www.medpagetoday.com/infectiousdisease/covid19/85545
Mar 22nd, 2020 - Rheumatologists may be in a unique position to consult and help in the management of patients with severe disease caused by COVID-19, said experts. "Some of the drugs that appear promising for patients who are severely ill with COVID-19 are those ...
https://www.medpagetoday.com/rheumatology/arthritis/84098
Dec 24th, 2019 - This story was originally published Sept. 4, 2019. As part of MedPage Today's year-end review of 2019's top stories, we are republishing it along with an update on what has happened since. A new, potentially life-threatening parenchymal lung disea...
https://www.medpagetoday.com/rheumatology/arthritis/81966
Sep 4th, 2019 - A new, potentially life-threatening parenchymal lung disease is increasingly being detected in patients with systemic juvenile idiopathic arthritis (sJIA), according to recent reports. Systemic JIA is distinct from other forms of JIA in that the a...